Mylan N.V.’s (MYL) abbreviated new drug application seeking approval of generic version of GlaxoSmithKline’s respiratory drug Advair Diskus is under FDA review – with a decision slated for March 28, 2017.Advair Diskus is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). The last patent on Advair Diskus expired in August 2016. Advair Diskus generated about $4.7 billion in sales last year.